(Q44469108)

3 December 2017

A lupus-like syndrome associated with infliximab therapy (English)

1 reference

3 December 2017

Jason B Klapman

1

1 reference

3 December 2017

Daniel Ene-Stroescu

series ordinal

2

1 reference

3 December 2017

Michael A Becker

series ordinal

3

1 reference

3 December 2017

Stephen B Hanauer

series ordinal

4

1 reference

3 December 2017

language of work or name

1 reference

1 May 2003

1 reference

Inflammatory Bowel Diseases

3 December 2017

1 reference

3 December 2017

9

1 reference

3 December 2017

3

1 reference

3 December 2017

176-178

1 reference

TNF alpha--a pivotal role in rheumatoid arthritis?

3 December 2017

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Cytokines and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

An in vitro assay for detection of glomerular binding IgG autoantibodies in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200305000-00005

10.1097/00054725-200305000-00005

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference